State of the art of radiomic analysis in the clinical management of prostate cancer: A systematic review

[Display omitted] •Radiomics is a quickly developing discipline.•Radiomics is promising for prostate cancer characterization in the staging phase.•MRI is the most investigated imaging modality in radiomic analyses at present.•Results gathered so far are encouraging but often exploratory and non-comp...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2022-01, Vol.169, p.103544-103544, Article 103544
Main Authors: Ghezzo, Samuele, Bezzi, Carolina, Presotto, Luca, Mapelli, Paola, Bettinardi, Valentino, Savi, Annarita, Neri, Ilaria, Preza, Erik, Samanes Gajate, Ana Maria, De Cobelli, Francesco, Scifo, Paola, Picchio, Maria
Format: Article
Language:English
Subjects:
Clinical management
Humans
Magnetic Resonance Imaging
Male
MRI
PET
Prostate cancer
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - therapy
Radiomics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •Radiomics is a quickly developing discipline.•Radiomics is promising for prostate cancer characterization in the staging phase.•MRI is the most investigated imaging modality in radiomic analyses at present.•Results gathered so far are encouraging but often exploratory and non-comparable. We present the current clinical applications of radiomics in the context of prostate cancer (PCa) management. Several online databases for original articles using a combination of the following keywords: “(radiomic or radiomics) AND (prostate cancer or prostate tumour or prostate tumor or prostate neoplasia)” have been searched. The selected papers have been pooled as focus on (i) PCa detection, (ii) assessing the clinical significance of PCa, (iii) biochemical recurrence prediction, (iv) radiation-therapy outcome prediction and treatment efficacy monitoring, (v) metastases detection, (vi) metastases prediction, (vii) prediction of extra-prostatic extension. Seventy-six studies were included for qualitative analyses. Classifiers powered with radiomic features were able to discriminate between healthy tissue and PCa and between low- and high-risk PCa. However, before radiomics can be proposed for clinical use its methods have to be standardized, and these first encouraging results need to be robustly replicated in large and independent cohorts.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2021.103544